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 OPINION OF THE COURT 
 _______________ 
 
JORDAN, Circuit Judge. 
Thomas Young appeals the dismissal of his class action complaint against Johnson 
& Johnson (“J&J”) asserting various state law causes of action based on allegedly 
deceptive labeling of certain J&J products.  For the following reasons, we will affirm.  
I. Background 
J&J manufactures Benecol
®
 Regular Spread and Benecol
®
 Light Spread 
butter/margarine substitutes (collectively “Benecol”).  In two locations on the outside of 
the Benecol label
1
 and one on the inside of the label, it states that Benecol contains “NO 
                                              
1
 The Benecol label wraps around and is separate from the container holding the 
actual spread.  Representations and disclaimers located on the inside of the Benecol label 
are not visible until the label is removed from the product.   
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TRANS FAT.”  (App. at 47-48.)  The “Nutrition Facts” box, which is also on the outside 
of the label, notes the “Amount/Serving” of “Trans Fat” as “0g.”  (Id. at 47.)  Directly 
above the Nutrition Facts box on the outside of the label is the statement “No Trans Fatty 
Acids.”  (Id.)  
The label also states in large letters immediately below the Benecol name in two 
locations on the outside and once on the inside that the product is “Proven to Reduce 
Cholesterol.”  (App. at 47-48.)  The outside of the label provides the basis for that claim, 
stating, in relevant part, that “[p]roducts containing 0.7 g or more of plant stanol esters 
per serving eaten twice a day with meals for a daily intake of at least 1.4 g may reduce 
the risk of heart disease as part of a diet low in saturated fat and cholesterol.”  (App. at 
47-48.)  The outside of the label also states that “[e]ach serving contains 0.85 g of Plant 
Stanol Esters (0.5 g plant stanols)” and that “Plant Stanol Esters[’] proven ability to lower 
cholesterol is supported by over 25 studies, including one in the New England Journal of 
Medicine.”  (App. at 47-48 (emphasis in original).)  The inside of the label further claims 
that Benecol “offers you a great way to reduce your cholesterol” because it “[r]educes 
‘bad’ (LDL) cholesterol,” “[r]educes total cholesterol,” and “[b]locks cholesterol from 
being absorbed into your body.”  (App. at 47, 49.) 
Young asserts that Benecol’s representations concerning its trans fat content and 
cholesterol-lowering capability are false and misleading because Benecol contains small 
amounts of trans fats (also referred to as “partially hydrogenated oil”) that may be 
detrimental to heart health.  He further alleges that he paid a premium price for Benecol, 
in reliance on its false and misleading nutrient content and health claims.     
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Young filed a five-count complaint in the United States District Court for the 
District of New Jersey asserting claims for violations of the New Jersey Consumer Fraud 
Act, N.J. Stat. Ann. § 56:8-1, et seq., and the New York General Business Law § 349 (on 
behalf of a putative New York subclass), breach of express warranties and of the implied 
covenant of merchantability, and unjust enrichment.  The District Court granted J&J’s 
motion to dismiss, concluding that Young had not adequately pled an injury-in-fact and 
therefore lacked standing, and that his claims were expressly preempted by the Food, 
Drug and Cosmetic Act (“FDCA”), 21 U.S.C. § 301 et seq., as amended by the Nutrition 
Labeling and Education Act (“NLEA”), 21 U.S.C. § 343-1. 
This timely appeal followed. 
II. Discussion2 
 The NLEA expressly preempts any state-imposed requirement for nutrition 
labeling of food, or with respect to nutritional or health-related claims, “that is not 
identical to the requirement” set forth in the relevant provisions of the Act.  21 U.S.C. 
§ 343-1(a)(4), (a)(5).  Young asserts that his state law causes of action based on J&J’s 
alleged misrepresentations about Benecol are not preempted because they seek to impose 
                                              
2
 The District Court had jurisdiction pursuant to the Class Action Fairness Act, 28 
U.S.C. § 1332(d).  We have jurisdiction under 28 U.S.C. § 1291.  “To survive a motion to 
dismiss [under Rule 12(b)(6)], a complaint must contain sufficient factual matter, 
accepted as true, to state a claim to relief that is plausible on its face.”  Sheridan v. NGK 
Metals Corp., 609 F.3d 239, 263 n.27 (3d Cir. 2010) (quoting Ashcroft v. Iqbal, 556 U.S. 
662, 678 (2009)) (internal quotation marks omitted).  “A claim has facial plausibility 
when the plaintiff pleads factual content that allows the court to draw the reasonable 
inference that the defendant is liable for the misconduct alleged.”  Id. (quoting Iqbal, 556 
U.S. at 678) (internal quotation marks omitted).  
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requirements that are identical to those set forth in the NLEA.
3
  His arguments 
correspond to the two groups of claims made on the Benecol package: (1) that the 
product does not contain trans fats (the “Trans Fat Claims”); and (2) that it is proven to 
reduce cholesterol because it contains beneficial plant stanol esters (the “Cholesterol 
Claims”).  We discuss preemption as it pertains to each of those sets of claims 
separately.
4
 
A. Trans Fat Claims 
The essence of Young’s argument regarding the Trans Fat Claims is that, although 
the regulations authorize Benecol to claim that it contains “0g of Trans Fat Per Serving,” 
they do not expressly permit a claim of “NO TRANS FAT” for the product as a whole. 
Thus, Young contends that he “seeks to prohibit false and misleading nutrient content 
                                              
3
 The District Court did not reach Young’s alternative theories of liability based on 
breach of express and implied warranties and unjust enrichment.  He does not press those 
theories on appeal, and we do not address them. 
4
 The District Court also concluded that Young lacked standing because he had not 
pled a sufficient injury-in-fact.  We note that cases from the District of New Jersey have 
found that plaintiffs have standing to sue under New Jersey’s Consumer Fraud Act 
(“CFA”) when they have alleged financial injuries based on their purchase of a product 
that did not have the attributes it claimed.  See, e.g., Lieberson v. Johnson & Johnson 
Consumer Cos., Inc., 865 F. Supp. 2d 529, 537 (D.N.J. 2011) (finding standing under the 
CFA based on consumer’s assertion that she would not have purchased the product but 
for its claim that it would help her baby to sleep better); Green v. Green Mountain Coffee 
Roasters, Inc., 279 F.R.D. 275, 280 (D.N.J. 2011) (finding standing under the CFA based 
on consumer’s allegation that he purchased a coffee maker based on allegedly false 
representation that it would brew a programmed quantity of coffee); Zebersky v. Bed Bath 
& Beyond, Inc., No. 06-1735, 2006 WL 3454993, at *2 (D.N.J. Nov. 29, 2006) 
(concluding that a consumer “alleged an injury in fact sufficient to withstand [a] motion 
[to dismiss]” under the CFA because she alleged “that the goods purchased were of 
inferior quality to what was represented by defendants”).  Though tenuous, Young’s 
standing under the specific facts of this case is sufficient for us to consider the merits.   
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claims regarding trans fat content per product.  Prohibition of such statements is not 
inconsistent with the FDA’s regulation allowing nutrient content claims about trans fat 
per serving.”  (Appellant’s Opening Br. at 25 (emphasis in original).) 
The FDA nutrition information regulation that covers trans fat content generally 
requires “[a] statement of the number of grams of trans fat in a serving,” but further 
provides that “[i]f the serving contains less than 0.5 gram [of trans fat], the content, when 
declared, shall be expressed as zero.”  21 C.F.R. § 101.9(c)(2)(ii).  The regulation also 
says that such amounts are deemed to be “insignificant amounts” for purposes of the 
“declaration of nutrition information.” Id. § 101.9(f)(1).  Benecol contains less than 0.5 
grams of trans fat per serving, and therefore properly discloses that it contains “0g of 
trans fat” per serving in the Nutrition Facts box. 
While FDA regulations do not specifically say a product can advertise itself as 
containing “NO TRANS FAT” when it has an insignificant amount, they do allow 
“nutrient content claim[s],” id. § 101.13(b), such as claims that a product contains “no 
fat” or “no saturated fat,” without reference to a per-serving limitation, provided that the 
product indeed contains less than 0.5 grams per serving, id. § 101.62(b)(1), (c)(1).  And 
more broadly, FDA regulations permit the label to contain a “statement about the amount 
or percentage of a nutrient” if it is “not false or misleading.”  Id. § 101.13(i)(3).   
The FDA has long recognized the potential for a discrepancy between required 
disclosure of “zero grams per serving” and an accurate nutrient content claim that the 
product is not, in fact “free” of the nutrient in question.  Because “[s]uch declarations 
could be confusing to consumers, and this consequence is unintended[,] ... the 
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determination of whether a product is free of a nutrient [is] based on the value of the 
nutrient ... per labeled serving.”  58 Fed. Reg. 44025 (Aug. 18, 1993).  In the interest of 
clarity and consistency with the nutritional information, FDA regulations therefore 
authorize nutrient content claims based on per serving amounts, even if those claims are 
not entirely accurate on a per product basis.  For example, the regulations authorize 
nutrient content claims that a food is “calorie free” if it contains less than 5 calories per 
serving, 21 C.F.R. § 101.60(b)(1); that a food is “sodium free” if it contains less than 5 
milligrams of sodium per serving, id. § 101.61(b)(1); and that a food contains “no fat” or 
“no saturated fat” if it contains less than 0.5 grams per serving, id. § 101.62(b)(1), (c)(1).  
Consequently, the “NO TRANS FAT” claim on the Benecol label is not “misleading” as 
that term is used in 21 C.F.R. § 1.13(i)(3), and is authorized under that provision, even if 
a “no trans fat” claim is not expressly contemplated by the regulations.5 
Nutrient content claim regulations promulgated under the NLEA thus authorize 
the Trans Fat Claims, based on the per serving amount of trans fats that the product 
contains.  Because Young seeks to bar that disclosure under state law, in effect enforcing 
                                              
5
 Three other courts that have recently reached the same conclusion.  See Carrea v. 
Dreyer’s Grand Ice Cream, Inc., 475 F. App’x 113, 115 (9th Cir. 2010) (concluding that 
“0g Trans Fat … is an express nutrient content claim that the [FDA] not only permits, but 
further instructs should mirror the Nutrition Facts panel” (citations omitted)); Chacanaca 
v. Quaker Oats Co., 752 F. Supp. 2d 1111, 1121 (N.D. Cal. 2010) (concluding that 
“‘nutritionally insignificant amounts’ of less than 0.5 grams trans fats means the same 
thing, according to [FDA] regulations, as ‘0 grams,’” and that “the use of the latter 
language in a[] ... nutrient content claim would not be misleading within the meaning of 
[the FDCA] or any of its regulations”); Reid v. Johnson & Johnson, No. 11-cv-01310-L-
BLM, 2012 WL 4108114, at *10 (S.D. Cal. Sept. 18, 2012) (concluding that FDA 
regulations authorize the “no Trans Fat” and “No Trans Fatty Acids” claims on the 
Benecol label because “[m]aking a distinction between ‘No Trans Fat’ and ‘0 grams trans 
fat’ is unreasonable”).   
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state law requirements that are not identical to the NLEA, his action is expressly 
preempted as it relates to those claims. 
B. Cholesterol Claims 
Young contends that the FDCA does not preempt his action with respect to the 
Cholesterol Claims because he seeks to enforce state law requirements that are identical 
to regulations prohibiting false and misleading health claims.  Young argues that the 
District Court failed to distinguish between “Defendant’s false claim that Benecol as a 
whole is ‘Proven to Reduce Cholesterol’ [and] the FDA-approved claim that plant 
sterol/stanol esters are ‘Proven to Reduce Cholesterol.’”  (Appellant’s Opening Br. at 26.)   
Two interrelated FDA regulations, 21 C.F.R. §§ 101.14 and 101.83, govern the 
Benecol Cholesterol Claims.  J&J’s claim that the product is “Proven to Reduce 
Cholesterol” is a “health claim” subject to 21 C.F.R. § 101.14 because it is based on the 
fact that the product includes particular amounts of plant stanol esters, and therefore 
“characterizes the relationship of a[] substance to a disease or health-related condition.”  
Id. § 101.14(a).  Food labeling may not include a health claim, whether express or 
implied, unless the claim is “specifically provided for” in 21 C.F.R. §§ 101.70-83, and 
the claim “conforms to all general provisions of [§ 101.14].”  Id. § 101.14(e)(1), (e)(2).  
The general provisions of § 101.14 require, inter alia, that health claims must be 
“complete, truthful, and not misleading.”  Id. § 101.14(d)(2)(iii).  The Benecol 
Cholesterol Claims also come under 21 C.F.R. § 101.83, which specifically provides for 
health claims “which summarize the relationship between diets that include plant 
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sterol/stanol esters and the risk of [heart disease] and the significance of the relationship.” 
Id. § 101.83(d)(3).   
 Young argues that J&J’s claim that its product (rather than the plant stanol esters 
the product contains) is “Proven to Reduce Cholesterol” is not “specifically provided for” 
in §§ 101.70-101.83 (as required by § 101.14(e)), and that it violates § 101.14(d) because 
it is false and misleading.  The first argument is directly contradicted by § 101.83, which 
permits a food product to make a health claim based on plant stanol esters if “the food 
product ... contain[s] ... [a]t least 1.7 g of plant stanol esters ... per reference amount 
customarily consumed of the food products eligible to bear the health claims, specifically 
spreads ... .”  21 C.F.R. § 101.83(c)(2)(iii)(A)(2) (emphasis added).6  Thus, “[t]he 
regulations state the minimum amount of plant stanol esters that a product must contain 
before it can bear health claims, but[] ... do not require that products show that they 
effectively reduce cholesterol as formulated.”  Reid v. Johnson & Johnson, No. 11-cv-
01310-L-BLM, 2012 WL 4108114, at *9 (S.D. Cal. Sept. 18, 2012) (internal quotation 
marks omitted).    
 Young’s second argument, that the “Proven to Reduce Cholesterol” claim is false 
and misleading, rests on the assertion that the claim is expressed with reference to the 
product itself rather than to the plant stanol esters it contains, and that the product 
                                              
6
 In 2003, the FDA reduced the amount of plant stanol esters required for a food to 
make the health claims listed in 21 C.F.R. § 101.83 to 0.4 grams per serving, and a total 
daily intake of 0.8 grams, but the regulation was not revised to reflect that change. 
Benecol contains more than those required amounts, and Young does not appear to 
challenge Benecol’s ability to make cholesterol-lowering claims based on the amount of 
plant stanol esters it contains. 
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contains harmful trans fats.  Both of those facts are irrelevant.  It is of no consequence 
that the claim may be read as referring to the product rather than to the plant stanol esters 
it contains because the regulations expressly authorize the product to make the health 
claim.  See 21 C.F.R. § 101.83(c)(2)(iii)(A) (describing the “[n]ature of the food eligible 
to bear the claim” in terms of the amount of plant stanol esters that the “food product 
shall contain”).  Also, the regulations set forth a “model health claim” that speaks in 
terms of “[f]oods containing” and “servings of foods containing” the specified amounts 
of plant stanol esters.  Id.  § 101.83(e)(2)(i), (e)(2)(ii).  Likewise, the fact that Benecol 
contains small amounts of trans fats does not render its Cholesterol Claims false and 
misleading because the Cholesterol Claims are authorized by the regulations based solely 
on the product’s plant stanol ester content, without reference to other nutrients such as 
trans fats.  Id.  §  101.83(c)(2)(iii)(A)(2).  
In summary, J&J is permitted to make heart health claims that relate to Benecol 
based on the product’s plant stanol esters content.  The Cholesterol Claims are authorized 
by FDA regulations and are not false or misleading.  Because Young’s state law action 
seeks to impose standards that are not identical to those set forth in the regulations, it is 
expressly preempted by the NLEA as it relates to those claims.   
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III. Conclusion 
 The District Court therefore properly dismissed Young’s complaint because all of 
his theories of liability are expressly preempted.
7
  We will therefore affirm the District 
Court’s ruling. 
                                              
7
 Young also argues that the District Court abused its discretion when it dismissed 
his complaint with prejudice, effectively denying him leave to amend.  “Under [Federal 
Rule of Civil Procedure] 15(a), futility of amendment is a sufficient basis to deny leave to 
amend.”  Great W. Mining & Mineral Co. v. Fox Rothschild LLP, 615 F.3d 159, 175 (3d 
Cir. 2010).  “Futility means that the complaint, as amended, would fail to state a claim 
upon which relief could be granted.”  In re Merck & Co. Sec., Inc., Derivative & ERISA 
Litig., 493 F.3d 393, 400 (3d Cir. 2007) (internal quotation marks omitted).  Therefore, a 
court need not grant leave to amend if “the amendment would not cure the deficiency.”  
Shane v. Fauver, 213 F.3d 113, 115 (3d Cir. 2000). In this case, the District Court 
dismissed Young’s complaint because his claims are expressly preempted.  That is a 
determination of law, not fact.  See Roth v. Norfalco LLC, 651 F.3d 367, 374 (3d Cir. 
2011) (noting that a district court’s “preemption ... determinations were based on 
questions of law”).  Any attempt by Young to amend the factual allegations in his 
complaint would not have saved it as a matter of law, and the District Court did not abuse 
its discretion when it dismissed the complaint with prejudice. 
